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Introduction: Pulmonary vein isolation (PVI) is considered to be a cornerstone of invasive
therapy of paroxysmal atrial fibrillation (PAF). However, numerous technologies appeared
on the market during last 10 years and besides typical ‘‘point-by-point’’ ablation, other
‘‘single-burn’’ technologies or remote navigation emerged.
Goal: The aim of this article is to summarize single center experience with PVI using
different technologies.
Methods and results: The study was conducted in partially retrospective and mainly
prospective manner. Consecutive cohorts of patients with PAF were followed after their
index procedure using four different systems (CARTO XP, pulmonary vein ablation
catheter (PVAC), CARTO3 and Sensei robotic system). After 3 month blanking period,
repeated 7 day-Holters were carried out every 3 months following the index procedure,
which consisted of catheter-based radiofrequency PVI. Documented episodes of AF
lasting 460 s on any of these 7-day Holters were considered a failure of treatment.
Using of the PVAC technology was associated with the shortest procedure duration
when compared to any other system (po0.0001 for all) and significant shortening of
fluoroscopic time when compared to CARTO XP (po0.0001). Using of novel CARTO3
mapping system or robotic navigation led to significant decrease of procedural time
when compared to older 3D mapping system (po0.0001). Arrhythmia free survival at 12
months following the index procedure was 65.8%, 68.7%, 75% and 76.1% when using
CARTO XP, PVAC, CARTO3 and robotic navigation, respectively. Using of either CARTO3
or robotic navigation system led to significant improvement of AF-free survival (log
rank po0.01). One major vascular complication was recorded in the robotic group of
patients while none in other groups. No minor or major late complications (beyond 30
days following the index procedure) were noted in any of the groups.ed by Elsevier Urban & Partner Sp.z o.o. on behalf of The Czech Society of Cardiology.
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c o r e t v a s a 5 4 ( 2 0 1 2 ) e 3 9 3 – e 4 0 0e394Conclusions: Novel technologies bring significantly better results in terms of arrhyth-
mia recurrence and allow for shorter procedure duration and lower radiation burden
both for patients and the operating physicians.
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.1. Introduction
Pulmonary vein isolation (PVI) is considered to be a corner-
stone of invasive therapy of paroxysmal atrial fibrillation
(PAF) [1,2]. However, numerous technologies emerged on the
market during last 10 years and typical ‘‘point-by-point’’
ablation around the pulmonary vein (PV) ostia or antra was
originally intended to be replaced by ‘‘single burn’’ technol-
ogies, which requires only one or a few radiofrequency (RF) or
other energy applications to achieve pulmonary vein isola-
tion, thus making the procedure more simple, shorter, safer
and at the same time effective [3–6]. In parallel, 3D mapping
systems evolved and recently, the electrophysiologists have
gained the possibility of appropriate contact force measure-
ment [7], a believed ‘‘last piece in the puzzle’’ tool to achieve
durable electrical disconnection of the PVs, remote catheter
navigation or real-time visualization of all catheters within
the heart chamber. The precipitous testing of these new
technologies, which can be thoroughly documented in the
field of RF ablation for PAF during last few years [8], poses
inherent risk of non-validated use, as one technology is
rapidly replaced by the other with no prove of superiority
and/or non-inferiority with all potential consequences.
The purpose of this article is to summarize experience of
an expert single center with PVI using four different technol-
ogies. Rather than randomized comparison, we would like to
provide consecutive cohort assessment in this analysis, with
stress to the risks and benefits both for the patients and for
the operators.2. Methods
2.1. Patients and procedure
We partially retrospectively and mainly prospectively ana-
lyzed four groups of consecutive patients treated at our clinic
between 2009 and 2011, who underwent catheter treatment
for PAF with respect to the used technology and clinical
results:(1) Patients treated with conventional ‘‘point-by-point’’ man-
ual ablation using old generation 3D mapping system
CARTO XP (Biosense Webster Inc., Diamond Bar, CA,
USA)—group A.(2) Patients treated with conventional ‘‘point-by-point’’ man-
ual ablation using the new generation 3D mapping system
CARTO3 (Biosense Webster Inc., Diamond Bar, CA, USA)
—group B,(3) Patients treated with decapolar circular ablation catheter
(PVACTM, Medtronic, USA) combined with a multichannel,duty-cycled RF generator (GENius, Medtronic, USA)—
group C,(4) Patients treated using robotic technology (Senseis X
Robotic Catheter System, Hansen Medical, USA) and 3D
mapping system NavX or later EnsiteVelocity (St. Jude
Medical, USA)—group D.
AF was considered paroxysmal if patients had a history of
recurrent, self-terminating episodes of arrhythmia sponta-
neously converted to normal SR or either electrically of
pharmacologically cardioverted within 48 h if the symptoms
were severe. Patients without structural heart disease were
not required to test antiarrhythmic drugs prior to the proce-
dure. Patients with persistent AF were excluded from this
study as well as patients with significant structural abnorm-
alities (left atrial (LA) dimensionZ50 mm, left ventricular
ejection fraction (LVEF)r50%, valvular insufficiency and/or
stenosisZgrade 3, hypertrophic cardiomyopathy with septal
thicknessZ20 mm). Transoesophageal echocardiography was
performed 1 day prior to procedure to exclude LA thrombus.
2.2. CT imaging
Anatomy of the LA and PVs is known to be highly individual
and variable. A 64-slice CT scan (AquilionTM 64 TSX-101 A,
Toshiba) was performed on the day prior to the ablation
procedure, with subsequent 3D reconstruction of the anat-
omy using the CARTO MERGETM or CARTO3TMsoftware (Bio-
sense Webster Inc., Diamond Bar, CA, USA) software to
ensure that all PVs were targeted for ablation.
2.3. Ablation procedure
All procedures were done under conscious sedation using
fentanyl or combination of fentanyl and diazepam. Heparin
was given after accessing the LA in a loading dose of 100 IU/
kg and continuous infusion with the target ACT between 280
and 330 s. Oral anticoagulation (coumadin) was restarted in
all patients directly after the procedure, using low-molecular
weight heparin for bridging until INR exceeded 2.0.
During procedures using CARTO XP or CARTO3 systems PV
antra were targeted by contiguous focal lesions deployed at a
distance45 mm from the ostia of the PVs, creating a circum-
ferential line around both ipsilateral veins (Fig. 1). Radio-
frequency energy was applied using 3.5 mm irrigated tip
NAVISTARs THERMOCOOLs catheter (Biosense Webster
Inc.) with temperature limitation of 45 1C and radiofrequency
energy up to 35 W. Use of circular mapping catheter (LASSO ,s
Biosense Webster Inc., Diamond Bar, CA, USA) to confirm
absence of local PV potentials during sinus rhythm or pacing
Fig. 1 – Example of pulmonary vein isolation by ‘‘point-by-
point’’ technique under 3D electromagnetic guidance using
CARTO system. A contiguous ablation line (red dots) is
drawn around the ipsilateral pulmonary veins.
Posteroanterior view, A: auricle; LSPV: left superior
pulmonary vein; LIPV: left inferior pulmonary vein; RSPV:
right superior pulmonary vein; and RIPV: right inferior
pulmonary vein.
Fig. 2 – Example of the isolation of the left superior
pulmonary vein using PVAC system. The catheter is
introduced in the left atrium using over-the-wire technique,
the J-shaped wire is parked in the left superior pulmonary
vein (arrow) and the catheter is pushed against the venous
antrum. TS: 9 F steerable trans-septal sheath and CS:
catheter introduced in the coronary sinus.
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appropriate, was mandatory in each procedure.
A detailed description of PVAC ablation procedure was
described in details elsewhere [9]. In brief, after successful
transseptal puncture the PVAC catheter was introduced to the
LA via a 9 F steerable transseptal sheath (Channel, BARD
Electrophysiology, Lowell, MA, USA) (Fig. 2). The standard abla-
tion setting was 4:1 bipolar to unipolar RF energy application
during 60 s, with a power limit of 8Wand target temperature of
60 1C. Overlapping applications were performed until the local
antral voltage abated (Fig. 3). PVI with entrance block was
verified by mapping inside each vein using PVAC and finally at
the end of the procedure using conventional circular mapping
catheter (LASSOs, Biosense Webster Inc., Diamond Bar, CA,
USA) showing absence of local PV potentials during sinus
rhythm or pacing from the coronary sinus and/or left atrial
appendage, when appropriate.
The PVI in the Hansen group wasmade in a similar fashion as
in the CARTO groups with following differences: (1). Reconstruc-
tion of the LA was performed using EnsiteNavX navigation
system (St. Jude Medical, St. Paul, MN, USA). (2) Robotic steerable
sheath ARTISANTM (Hansen Medical, Inc. Mountain View, CA,
USA) was introduced in the LA after accessing the chamber with
double transseptal puncture. (3) Radiofrequency energy was
delivered by a 4mm tip Celsius THERMOCOOLs catheter
(Biosense Webster Inc.) for up to 60 s on each spot with
temperature limitation of 45 1C and radiofrequency energy up
to 25–30W. Contact force of the Artisan catheter was continu-
ously monitored and kept within the range of 10–30 g (Fig. 4).2.4. Follow-up
Three month blanking period to allow for tissue healing and
lesion consolidation was planned and any recurrence of AFduring this period was not considered failure of treatment.
Patients were advised to continue their antiarrhythmic ther-
apy that had proven to be previously ineffective, during this
blanking period. After one month, the first 7-day Holter was
performed, and if no arrhythmia recurrence was detected,
discontinuation of all antiarrhythmic drugs was advised.
Further 7-day Holters were performed every 3 months after
the procedure until the 24th month following the index
procedure. Documented episodes of AF lasting 460 s on any
of these three 7-day Holters were considered a failure of
treatment. In addition, if patients felt palpitations and no
arrhythmias were detected on the 7-day Holter, monitoring of
the heart rhythm was done using a patient-activated, simple
to use Holter device taking down a one minute ECG recording
during symptoms. Patients remained on oral anticoagulation
therapy with vitamin K antagonists with the target INR
2.5–3.0 throughout the whole study if the CHADS2 (or later
CHA2DS2VASc) was Z2. In patients with lower CHADS2 score
the anticoagulation therapy was discontinued after 6 months
following the index procedure if no arrhythmia was detected
both at the 3rd and 6th month of the follow-up.2.5. Statistical analysis
Statistical analysis was performed using MedCalc software,
ver. 12.3.0.0. Continuous variables are expressed as mean7-
standard deviation. Categorical variables are presented as
absolute numbers and percentages. Comparisons between
the two groups were made with a Fisher’s exact test for
categorical variables and a one-way ANOVA test for
Fig. 3 – Example of the isolation of the left inferior pulmonary vein using PVAC system. (A) Before ablation, signals could be
recorded from all five pairs of the circular ablation catheter. When RF application is started (RF on), signals are dumped by the
noise from the RF generator and atrial ectopic beats are usually present. (B) After a 60 s application, no more signals are
present and an ectopic, non-conducted pulmonary vein potential (arrow) is proof of an exit block and electrical isolation.
Fig. 4 – Pulmonary vein isolation using Sensei robotic
system and EnsiteNavX navigation system. The encircling
of the left pulmonary veins was started at the roof of the left
upper pulmonary vein antrum and continued down to left
inferior pulmonary vein on the posterior wall of the left
atrium (red dots). Fluoroscopic image, intracardiac
echocardiography image and 3D map are integrated into
one screen and contact force curve of the Artisan robotic
catheter is instantaneously depicted in the left lower
portion of the image (arrow).
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tion (Shapiro–Wilk test), a non-parametrical Kruskal–Wallis
test was used, and for paired analysis a Mann–Whitney U-test
complemented with Bonferroni correction was applied to
limit a type I error at the levelo0.05. A p valueo0.05 was
considered statistically significant. The Kaplan–Meier
method was used for the arrhythmia-free survival curve.3. Results
Number of patients in group A, B, C and D and their baseline
clinical characteristics are listed in Table 1. The patients in all
four groups did not differ with respect to age, gender,concomitant diseases, antiarrhythmic therapy, that was
proved to be ineffective prior to invasive procedure, and both
left ventricular ejection fraction and left atrial diameter.3.1. Procedural outcome
Procedural characteristics are shown in Table 2. Upgrading
from CARTO XP (Group A) to any other technology (CARTO3,
PVAC and Hansen, groups B, C and D, respectively), signifi-
cantly shortened both total procedural time and X-ray time
(po0.001 for all). Moreover, using PVAC catheter for PVI was
connected with significant shortening of procedural time
when compared to any other technology (po0.001 for all).
There was no difference in procedural and fluoroscopic times
detected betweenmanual and robotic approach provided that
manual approach was performed using CARTO3 electromag-
netic mapping system, however, a trend towards shorter
procedural time appeared using manual approach (p¼0.06).
Fluoroscopic time was significantly longer in CARTO XP group
when compared to any other technology (po0.0001 for all).
Both CARTO3 and robotic group had shorter X-ray times than
PVAC group (po0.0001). Length of in-hospital stay did not
differ between the groups.
Acute success of PV isolation was also comparable between
all patient groups. Total RF time applied necessary to achieve
all PVI was significantly longer in Group A (CARTO XP) when
compared to any other technology (po0.001 for all).
In total 312 patients treated for PAF only one serious
complication was noted. The complication was linked with
the introduction of the robotic sheath (Artisan) in the Group
D. Due to extreme tortuosity of the right iliac vein this vein
was disrupted and continuous leakage of the blood to the
pelvic interstitium was proved by injecting contrast agent to
the femoral vein. Subsequently, the procedure had to be
prematurely stopped and extravasation was solved by percu-
taneous implantation of a wall-graft in the torn area without
any permanent sequellae. There was a higher cumulative
incidence of minor local vascular complications (AV fistula,
pseudoanerysm, large hematoma, thrombosis and infection)
in the CARTO XP group of patients when compared to other
patient groups (p¼0.02). All minor complications did not
Table 1 – Baseline clinical characteristics of four groups of patients with PAF treated with different technologies.
Group A Group B Group C Group D
CARTO XP CARTO 3 PVAC Sensei
N 81 77 79 75
Men 48 (59.3%) 44 (57.1%) 53 (67.1%) 42 (56%)
Women 33 (40.7%) 33 (42.8%) 26 (32.9%) 33 (44%)
Age (years) 5879 (33–81) 58710 (30–78) 59710 (31–81) 6179 (35–79)
Concomitant diseases
Hypertension 25 (30.9%) 24 (31.2%) 27 (34.2%) 17 (22.7%)
Diabetes 8 (9.9%) 4 (5.2%) 8 (10.1%) 5 (6.7%)
CAD 3 (3.7%) 3 (3.9%) 4 (5.1%) 2 (2.7%)
Antiarrhythmic therapy
Propafenone 36 (44.4%) 43 (55.8%) 38 (48.1%) 45 (60%)
Sotalol 18 (22.2%) 0 (0%) 22 (27.8%) 3 (4%)
Amiodarone 25 (30.9%) 28 (36.4%) 15 (19%) 27 (36%)
Flecainid 3 (3.7%) 1 (1.3%) 0 (0%) 0 (0%)
Dronedarone 0 (0%) 1 (1.3%) 0 (0%) 4 (5.3%)
None tested 9 (11.1%) 17 (22.1%) 14 (17.7%) 9 (12%)
LAD (mm) 41.575.2 (28–48) 41.275.2 (28–50) 41.175.2 (28–49) 42.975.5 (28–50)
LVEF (%) 6976 (55–78) 6776 (44–76) 6975 (60–80) 6778 (44–85)
CAD: coronary artery disease; LAD: left atrial diameter in parasternal long axis view; and LVEF: left ventricular ejection fraction
Table 2 – Procedural characteristics and early complications.
Group A Group B Group C Group D
CARTO XP CARTO3 PVAC Sensei
N 81 77 79 75
Total procedural time (min) 212746 134732
#,@ 105730 141727#
Fluoroscopic time (min) 26.478.3 8.774.5
&,£ 15.175.3 9.973.4£
RF application time (min) 49.7716.2 39.1711.8 20.076.0 27.979.3
% of veins acutely isolated 98.5%$ 100%$ 98%$ 99%$
Days of hospitalization 5.271.4$ 5.171.3$ 4.571.2$ 5.672.4$
Major early complications
Tamponade 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Atrio-esophageal fistula 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Gastroparesis 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Femoral vein injury requiring intervention 0 (0%) 0 (0%) 0 (0%) 1 (1.3%)
Phrenic nerve palsy 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Systemic infection/sepsis 1 (1.2%) 0 (0%) 0 (0%) 0 (0%)
Stroke/TIA 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Pulmonary vein stenosis 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Death 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Minor early complications
Pericardial effusion 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Large groin hematoma 1 (1.2%) 1 (1.3%) 1 (1.3%) 3 (4%)
AV fistula 2 (2.5%) 1 (1.3%) 0 (0%) 0 (0%)
Pseudoanerysm 6 (7.4%) 0 (0%) 1 (1.3%) 1 (1.3%)
Venous thrombosis 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Local groin infection 1 (1.2%) 0 (0%) 0 (0%) 0 (0%)
TIA: transitory ischemic attack. Large groin hematoma was defined as hematoma exceeding 100 cm2 of discolored skin in groins.
n po0.0001 for PVAC when compared to any other group.
$ p¼NS between the groups.
# po0.0001 for CARTO3 or Sensei when compared to group A.
@ p¼0.06 for CARTO3 when compared to group D.
& p¼NS for CATRO3 when compared to group D.
£ po0.0001 for CARTO3 or Sensei when compared to groups A or C.
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manual compression under sonographic guidance (AV fistu-
las, pseudoanerysms) or by local and/or systemic antibiotic
administration (groin infection).3.2. Clinical outcome
Arrhythmia free survival defined as absence of any supraven-
tricular arrhythmia (both atrial tachycardia and fibrillation
Fig. 5 – Arrhythmia-free survival in four different groups of patients depending on technology used for pulmonary vein
isolation (see the text for further details).
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Fig. 5. Mean follow-up reached 249792 days, 6187100 days,
2617100 days and 6317122 days in groups A, B, C and D,
respectively. Patients in groups B and D (CARTO3 and robotic
ablations) have shorter follow-up as these technologies were
available later.
Arrhythmia free survival without antiarrhythmic drugs did
not differ significantly between groups B and D (i.e. CARTO3
and Sensei) at 12th month (75% vs. 76.1%, p¼NS). Arrhythmia
free survival did not differ between groups A and C (i.e.
CARTO XP and PVAC) either, both at 12th and 24th month of
follow-up (68.7% vs. 65.8%, p¼NS, and 55.5% vs. 58.2%, p¼NS,
respectively). Both robotic and CARTO3 groups had signifi-
cantly better arrhythmia-free survival than CARTO XP and
PVAC groups (log rank po0.01 for all). No minor or major late
complications (beyond 30 days following the index proce-
dure) were noted in any of the groups.4. Discussion
The main result of our comparative study is that upgrading to
novel technologies used during PVI can bring significant
improvement in several aspects. First, the workflow of the
electrophysiology lab can be accelerated by shortening total
procedural time of AF ablation. Dramatic improvement was
noted especially with an introduction of duty-cycled RF
ablation with PVAC system. Entire duration of the procedure
was almost halved. By simultaneously applying RF energy to
virtually whole circumference of the PV antra it is possible to
achieve complete electrical isolation just by a few one minute
lasting burns. In our previous study we reported median of 6,
5, 4 and 4 burns needed for the disconnection of the left
upper, left lower, right upper and right lower pulmonary vein,
respectively [9], in line with other reports [5]. Also duration of
PVI procedures using PVAC catheter in our center is in
concordance with previous results described by other experi-
enced centers using this technology [5,10,11].Both CARTO3 mapping system and Sensei robotic technol-
ogy also made ablation procedures much quicker, albeit not
to such as an extent as PVAC catheter.
Second, the fluoroscopic times during AF ablations are of a
growing importance, especially in high-volume centers. Recent
multicenter Italian study showed significant decrease in mean
fluoroscopy time exposure comparing catheter treatment of AF
using older CARTO XP system and new generation CARTO3,
resulting in shortening of radiation exposure time almost to a
half (26715.1 min to 15.9712.3 min, po0.001) [12]. We currently
perform about 300 RF ablations for AF or complex supraventri-
cular arrhythmias per year in our center (only two operating
physicians). If a technology is able to save in average 17min of
X-ray time per procedure, as it was seen in our comparative
study (CARTO3 vs. CARTO XP), the cumulative fluoroscopic time
spared would reach hardly believable 85 h per year! Such a
dramatic decline of radiation exposure is even pronounced
during robotic ablations. While total X-ray time during Sensei
cases is comparable to manual ablations using CARTO3, the
absence of the operator in the operating theater during PV
isolation itself leads to further reduction of X-ray exposure, as
the operator is present in the lab only during catheter introduc-
tion, transseptal puncture and LA geometry creation (prepara-
tory phase of the procedure). Our previous study showed that in
such cases the mean X-ray exposure during robotic ablations of
PAF can be reduced down to 5.671.6 min [13].
Other ‘‘single shot’’ devices have been recently tested for PV
isolation in patients with PAF. In the cryoablation balloon study,
however, the total procedural time increased to 2117108min
with excessive fluoroscopy times of 52736min [14]. Recent
systematic review of published studies on cryoablation technol-
ogy, which pooled results of 23 trials, proved average procedural
time 206772min (range 108–371min), with fluoroscopy time of
46713min (range 20.1–84.5 min) [15]. Thus, even the shortest X-
ray time during cryoablation of PVs (about 20min) is at least
twice longer than mean time during ‘‘point-by-point’’ ablation
using CARTO3 or robotic technology, and the procedure itself is
prolonged by 60–70min in average. Another technology, that
was approved for PV isolation, but never got widely spread
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[16], was high-density mesh ablation/mapping catheter (Bard,
Lowell, MA, USA). Steinwender et al. reported procedural times
reaching 187736min and fluoroscopic times 34710min when
using this high-density mesh ablation [3]. Thus, based on the
published data and our results, the multipolar circular catheter
PVAC seems to be the only technology for PV isolation that
fulfils the expectations regarding shortening of an otherwise
lengthy procedure, together with reducing radiation exposure.
Recently, several safety issues regarding silent cerebral
microembolism (SCM) during RF ablation for AF have been
raised [17,18]. Silent cerebral embolism is occlusion of a blood
vessel in the brain due to an embolus that does not result in
any acute clinical symptoms, i.e. it is ‘‘silent’’. During an AF
ablation procedure, emboli may occur as a result of catheter
manipulation, sheath materials, anticoagulation levels, air
introduction during sheath/catheter introduction and/or as a
result of the ablation process [19,20]. Recent studies showed,
that phased RF energy using PVAC system led to significant
increase of SCM detected during diffusion weighted magnetic
resonance imaging (DW-MRI) when compared to irrigated RF
energy and cryoballoon (38.9% vs. 8.3% and 5.6%, respectively)
[17]. However, SCM has also been observed following most of
invasive cardiac procedures like cardiac valve replacement
(47%), by-pass grafting (34%), coronary angiography (15%),
carotid artery stenting (30%) and others [21]. Kruis et al.
performed independent review of 22 cardiac surgery trials
from the past 3 decades and showed that 66% of studies
reviewed showed no associations between SCM and risk of
cognitive decline, while 34% did [22]. The authors concluded
that based on the review of published studies they could not
confirm any association between microemboli and post-
operative cognitive decline. Furthermore, there is no associa-
tion between neurological symptoms and the presence of
post procedural acute cerebral lesions in any of the published
studies with AF ablation. Such a link would be difficult to find,
as even with cardiac surgery procedures conducted over last
30 years, no association has been established between cere-
bral microemboli and post-operative cognitive decline.
All four groups in our study seemed to be comparable with
respect to overall complication rate. There was no difference in
occurrence of major adverse clinical events like tamponade,
atrio-esophageal fistula, gastroparesis, phrenic nerve palsy,
embolic complications and death between the groups, as no
such complication happened in our cohort of patients. We
observed one serious complication during Artisan introduction,
which was finally fixed by wall-stent implantation into the iliac
vein without any permanent consequences. Therefore, we
strongly advise very careful introduction of the robotic sheath
under continuous fluoroscopic control. The best technique may
be to introduce cool-tip ablation catheter into the Artisan sheath
as far as possible, bend it in the vasculature, keep the close loop
of the ablation catheter so that the tip of catheter points always
backwards and push it together with the Artisan forward while
maneuvering with the ablation catheter handle until the right
atrium is reached. The use of longer 14 F sheaths for Artisan
introduction may be also beneficial, especially in obese patients.
Significantly higher incidence of local vascular complica-
tions in the CARTO XP group could be explained by our
former practice to introduce a 4 F sheath in the left femoralartery for invasive blood pressure measurement. After several
such complications we soon changed for radial artery cannu-
lation (in fact in majority of group C patients and in almost all
patients in groups B and D), which limited the incidence of
AV fistulas and pseudoaneurysms close to 1%.
Third, clinically relevant observation made in our study
was, that novel technologies are capable of improving
arrhythmia-free survival. We are awaiting long-term data
from our hospital registries, but AF-free survival without
antiarrhythmic drugs was improved by 10% in absolute
number with novel technologies like robotic ablations or
contemporary 3D mapping systems, at least at 12 months
following the index procedure. Recent advantages in contact
force measurement may be potent enough to ensure durable
PV electrical disconnection by enabling to create transmural
and continuous lesions and may increase clinical success
rate.5. Conclusion
The use of novel ablation technologies during pulmonary
vein isolation for paroxysmal atrial fibrillation significantly
reduces total procedural and fluoroscopic times whilst
achieving better clinical efficacy when compared to proce-
dures supported by older generation of mapping systems.
The safety profile of novel technologies seems to be
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